within Pharmacolibrary.Drugs.N_NervousSystem.N05A_Antipsychotics.N05AH53_OlanzapineAndSamidorphan;

model OlanzapineAndSamidorphan
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.6,
    Cl = 6.944444444444445e-06,
    adminDuration = 600,
    adminMass = 10 / 1000000,
    adminCount = 1,
    Vd = 1.0,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0013833333333333334,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>OlanzapineAndSamidorphan</td></tr><tr><td>ATC code:</td><td>N05AH53</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>10</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1000</td><td>L</td></tr>
    <tr><td>clearance:</td><td>25</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Olanzapine and samidorphan is a fixed-dose combination drug consisting of olanzapine, an atypical antipsychotic used for the treatment of schizophrenia and bipolar I disorder, and samidorphan, an opioid receptor antagonist used to mitigate olanzapine-induced weight gain. The combination (marketed as Lybalvi) is approved for use in adults.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters derived from healthy adult subjects after oral administration of olanzapine and samidorphan combination; values approximated from published prescribing information.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N05AH53 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end OlanzapineAndSamidorphan;
